Medtech's Launch Pipeline Is Thin. That Makes Every Submission More Expensive to Get Wrong.Read article →
The EU Just Made Drug Exclusivity Conditional. Device Regulatory Teams Should Watch Why.Read article →
This Week's Biggest Medtech Deals Have One Thing in Common: De-Risked Regulatory PathwaysRead article →